Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements
about
A Conserved Inhibitory Mechanism of a Lycorine Derivative against Enterovirus and Hepatitis C VirusReplication and Inhibitors of Enteroviruses and ParechovirusesStructure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypesBroad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses.3C Protease of Enterovirus 68: Structure-Based Design of Michael Acceptor Inhibitors and Their Broad-Spectrum Antiviral Effects against PicornavirusesIn vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C proteaseInhibition of human rhinovirus-induced cytokine production by AG7088, a human rhinovirus 3C protease inhibitorPharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteersIn vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor.In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity.Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteersBiosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase.Design, synthesis, and evaluation of inhibitors of Norwalk virus 3C protease.Antiviral Potential of a Novel Compound CW-33 against Enterovirus A71 via Inhibition of Viral 2A Protease.Potent inhibition of norovirus 3CL protease by peptidyl α-ketoamides and α-ketoheterocycles.Potent inhibition of enterovirus D68 and human rhinoviruses by dipeptidyl aldehydes and α-ketoamides.Antiviral activity of micafungin against enterovirus 71.Potent inhibition of norovirus by dipeptidyl α-hydroxyphosphonate transition state mimics.Stereoselective formation of a functionalized dipeptide isostere by zinc carbenoid-mediated chain extension.Amphotericin B Inhibits Enterovirus 71 Replication by Impeding Viral Entry.Development of antiviral agents for enteroviruses.Synthesis, Activity and Structure-Activity Relationship of Noroviral Protease Inhibitors.Susceptibilities of enterovirus D68, enterovirus 71, and rhinovirus 87 strains to various antiviral compounds.Picornaviral 3C protease inhibitors and the dual 3C protease/coronaviral 3C-like protease inhibitors.Enteroviral proteases: structure, host interactions and pathogenicity.Biocatalytic synthesis of chiral alcohols and amino acids for development of pharmaceuticals.The enterovirus 3C protease inhibitor SG85 efficiently blocks rhinovirus replication and is not cross-resistant with rupintrivir.Inhibition of norovirus 3CL protease by bisulfite adducts of transition state inhibitorsProstate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity.Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile 2008 (2nd edition): RNA viruses.Lack of respiratory and contact sensitizing potential of the intranasal antiviral drug candidate rupintrivir (AG7088): a weight-of-the-evidence evaluation.Strategies in the Design of Antiviral Drugs
P2860
Q26700115-3AF84A23-5ADC-4726-B3CF-EC7AD5D2C5D6Q26798463-123E6F80-A4AF-476E-812D-911E406B91CBQ27619756-2B006386-2840-4979-810C-E21E20043D1FQ27671667-D4B6C106-47B0-429A-8BE4-A32CCE4A02E8Q27676219-3DA5690A-1F95-4C0D-897B-34C61C3A0929Q28343611-F679584B-2795-4417-B6C4-E8A033450BFDQ28344143-109088BC-72D0-4FCC-89C5-CC4FEFE95140Q28345169-5A875ED6-ACEA-4815-B4D4-9253E4F94700Q30443266-7779E491-0FCE-4E85-AED1-ABE2FA22CA32Q30448643-1C076227-264D-4967-AF3F-36C0BE67EE32Q30449635-95F73BD4-3E1D-4801-BD60-8B525445C257Q30451184-55D137C1-C968-427F-8E21-33E536EEF45CQ34270281-CF8AEFB5-1F34-4DE2-8536-8F7F898E4E00Q35175461-33616B78-C605-4432-BE84-D69E3B2361DEQ35808685-0D6EEF25-203D-40AA-A17F-C2F0FDFE1051Q36074548-6C1784D5-97AB-447A-9F66-99A6E0798A77Q36421786-DD69B076-4D93-405A-89EB-014C355CC53AQ37002620-3C7EA1CF-3586-42DC-9099-53A693E0AD6FQ37028683-74CD1D67-DDAE-4023-B33E-88447CD8C325Q37186632-14B4BCD0-E887-4C0E-B341-EA82397597CEQ37243489-FE793D66-C7BB-4D72-ADC5-12FCC427A293Q37302641-6AB2B105-12CE-4BE1-8545-888F6603E1FEQ37304320-6A493814-7727-48FE-ACBB-ADE9981858E6Q37401695-BCC3A22C-10B0-4549-A2B1-2347F0F95393Q37658853-EC4C2142-4F65-4FF6-8755-20DA26A256C4Q38825350-A59F4EDF-1E9F-41FE-B4E6-451EF7B0E7B6Q39871919-54ACEF13-365C-4688-AF68-FA0F7B9C0B2BQ41175433-3A9BBEF6-B5C4-44B7-9CC3-32FA9211D19EQ41681368-15A285D2-DE9E-4C58-9160-C2078C5B931DQ41893698-58041AAB-A110-475D-A610-C62C29A7F658Q42981047-06068DA5-617B-4BD7-A20C-5E663C6C69D8Q43563933-D649B84C-EEE1-4D35-A994-BB6234A1D2E4Q56786281-107F09AF-3994-42D9-A125-C589EB2F659C
P2860
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Structure-based design, synthe ...... es as L-glutamine replacements
@ast
Structure-based design, synthe ...... es as L-glutamine replacements
@en
Structure-based design, synthe ...... es as L-glutamine replacements
@nl
type
label
Structure-based design, synthe ...... es as L-glutamine replacements
@ast
Structure-based design, synthe ...... es as L-glutamine replacements
@en
Structure-based design, synthe ...... es as L-glutamine replacements
@nl
prefLabel
Structure-based design, synthe ...... es as L-glutamine replacements
@ast
Structure-based design, synthe ...... es as L-glutamine replacements
@en
Structure-based design, synthe ...... es as L-glutamine replacements
@nl
P2093
P3181
P356
P1476
Structure-based design, synthe ...... es as L-glutamine replacements
@en
P2093
Dragovich PS
Fuhrman SA
Hendrickson TF
P304
P3181
P356
10.1021/JM9805384
P407
P50
P577
1999-04-01T00:00:00Z